- Conditions
- Multiple Sclerosis, Fatigue, Insomnia
- Interventions
- Suvorexant, Placebo
- Drug
- Lead sponsor
- Theodore R. Brown, MD MPH
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Kirkland, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 20,596
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma
- Interventions
- Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration, Sonrotoclax, Zanubrutinib
- Procedure · Other · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Food Hypersensitivity
- Interventions
- Amino Acid formula, Commercially available Amino Acid Formula
- Other
- Lead sponsor
- Société des Produits Nestlé (SPN)
- Industry
- Eligibility
- 2 Months to 12 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 9
- States / cities
- Huntington Beach, California • San Diego, California • Albany, Georgia + 6 more
- Conditions
- Infections, Human Immunodeficiency Virus and Herpesviridae, Infection, Human Immunodeficiency Virus
- Interventions
- GSK2248761 WBM Capsule, GSK2248761 WBM Tablet Formulation 1, GSK2248761 WBM Tablet Formulation 2, GSK2248761 WBM Tablet Formulation 3, GSK2248761 WBM Tablet
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- HIV Infections
- Interventions
- atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1,578 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2020
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
- Conditions
- Multiple Myeloma
- Interventions
- Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone, Bortezomib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 838 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 49
- States / cities
- Clovis, California • Santa Monica, California • New Haven, Connecticut + 41 more
- Conditions
- Sexually Transmitted Infections, HIV Infections
- Interventions
- Experimental
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Diego, California • Torrance, California
- Conditions
- Allergy
- Interventions
- MITE-T-FASTtest kit
- Other
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 5 Years to 15 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Hematologic Malignancy, Malignant Lymphoma
- Interventions
- Romidepsin, Ketoconazole
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Sarasota, Florida • Nashville, Tennessee
- Conditions
- Systemic Amyloidosis
- Interventions
- 124I-p5+14 Injection
- Drug
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Type I Diabetes Mellitus
- Interventions
- Artificial Pancreas Control Software
- Device
- Lead sponsor
- Legacy Health System
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Portland, Oregon
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema
- Interventions
- ENS-002
- Biological
- Lead sponsor
- Concerto Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • Beverly, Massachusetts • Austin, Texas
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Experimental: AIMS program - patient, No Intervention/Usual care
- Behavioral · Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 19 Years to 64 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Atopic Dermatitis
- Interventions
- Difamilast, Placebo
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more
- Conditions
- HIV Infections, Streptococcus Pneumoniae
- Interventions
- pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine
- Biological
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2013
- U.S. locations
- 6
- States / cities
- San Diego, California • Washington D.C., District of Columbia • Tripler AMC, Hawaii + 3 more
- Conditions
- Multiple Myeloma
- Interventions
- Velcade
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Asthma
- Interventions
- Not listed
- Lead sponsor
- University of Central Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Interventions
- azacitidine, donor lymphocyte infusion
- Drug · Biological
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 29 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HIV Infections
- Interventions
- social capital intervention, group-based health promotion intervention
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 29 Years · Male only
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Graft-versus-host-disease, GVHD
- Interventions
- Alpha 1-Antitrypsin
- Drug
- Lead sponsor
- John Levine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Duarte, California • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Follicular Lymphoma Grade 3
- Interventions
- Mosunetuzumab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 886 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 227
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 201 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- filgrastim, rituximab, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Malignant Tumors Lymphomas
- Interventions
- IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
- Biological
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Westwood, Kansas • Jackson, Mississippi + 1 more